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angiocarcinoma	 (iCCA),	5‐year	overall	 survival	of	about	30%	has	been	reported	 in	













The	sixth	challenge	 is	 that	even	after	a	complete	 resection	most	patients	develop	
recurrent	disease.	Recent	randomized	controlled	trials	found	conflicting	results	re‐
garding	 the	benefit	of	adjuvant	chemotherapy.	The	 final	challenge	 is	 to	determine	
which	patients	with	cholangiocarcinoma	should	undergo	liver	transplantation	rather	
than	resection.









where	 along	 the	 biliary	 tree.	 Intrahepatic	 (iCCA),	 perihilar	 (pCCA)	
and	distal	(dCCA)	cholangiocarcinoma	differ	in	tumour	characteris‐
tics	and	each	has	a	separate	American	Joint	Committee	on	Cancer	
(AJCC)	 staging	 system.1,2	 Consequently,	 they	 require	 a	 different	








tion	per	month	 for	pCCA.4,5	The	main	 goal	 of	 surgery	 for	 cholan‐
giocarcinoma	 is	a	complete	 (R0)	 resection	with	 low	post‐operative	
mortality.	This	goal	requires	a	multidisciplinary	team	with	dedicated	
radiologists,	 interventional	 radiologists,	 endoscopists,	 anaesthesi‐
ologists,	 intensivists,	 hepatologists,	 pathologists	 and	 hepatobiliary	
surgeons	 with	 both	 surgical	 oncology	 and	 vascular	 or	 transplant	
skills.	Outcomes	are	best	in	high‐volume	centres.6
The	 aetiology,	 pathogenesis,	 risk	 factors	 and	 epidemiology	 of	
cholangiocarcinoma	 are	 reviewed	 in	 separate	 contributions	 in	 this	
issue.	The	aim	of	this	review	is	to	summarize	the	diagnostic	work‐up	
and	treatment	of	patients	with	resectable	pCCA	or	iCCA.
















challenging	 after	 endoscopic	 stent	 placement.	 Moreover,	 the	
extent	of	 the	 tumour	determines	 the	 future	 liver	 remnant	 (FLR),	
which	determines	the	segments	to	be	drained	(see	also	section	on	
biliary	drainage).
Initial	 US	 examination	 shows	 intrahepatic	 biliary	 tree	 dila‐
tation,	 typically	 without	 dilatation	 of	 the	 gallbladder	 and	 the	
common	bile	duct.	CT	of	the	chest	and	abdomen	is	the	standard	
modality	for	staging	and	assessment	of	vascular	involvement.	MRI	
with	MRCP	and	diffusion‐weighted	 imaging	 can	be	of	 additional	
value	to	assess	the	biliary	extent	of	the	tumour.	Positron	emission	
tomography	(PET)	CT	should	not	be	routinely	used	in	the	diagnos‐
tic	work‐up	 because	 of	 low	 sensitivity	 and	 specificity.	However,	
in	 selected	patients	 (eg,	with	 increased	surgical	 risk	or	more	ad‐
vanced	disease),	PET	CT	may	be	justified	with	a	10%	yield	of	occult	








Preoperative	 biopsies	 and	 intraluminal	 brushings	 have	 a	 high	









MRCP	has	 replaced	 endoscopic	 retrograde	 cholangio‐pancrea‐
tography	(ERCP)	to	determine	the	biliary	extent	of	the	tumour.	ERCP	
with	endoluminal	biopsy	may	play	a	role	in	selected	patients	when	










•	 Preoperative	 biliary	 drainage	may	 do	more	 harm	 than	
good	in	patients	with	an	FLR	above	50%.	A	hepatobiliary	
surgeon	 experienced	 with	 cholangiocarcinoma	 should	
be	consulted	prior	to	biliary	drainage.
•	 Portal	 vein	 embolization	 (PVE)	 is	 recommended	 in	 pa‐
tients	with	an	FLR	of	less	than	40%.
•	 Multiple	 tumors	 and	 positive	 lymph	 nodes	 are	 poor	
prognostic	factors	for	iCCA,	but	do	not	preclude	5‐year	
survival	after	resection.























functional	 status	 (ie,	 co‐morbid	 conditions,	nutrition,	performance	







clearance),	 uptake	 and	 biotransformation	 (13C‐methacetin	 breath	
test,	LiMAx),	and	uptake	(hepatobiliary	scintigraphy).	These	function	
tests	 can	 be	 combined	with	 SPECT‐CT	 to	 differentiate	 functional	
from	 non‐functional	 liver	 tissue.18	 When	 the	 FLR	 is	 insufficient,	
strategies	 to	 increase	 the	 FLR	 should	 be	 considered	 (see	 sections	
below	on	portal	vein	embolization).
2.3 | Preoperative biliary drainage
Obstructive	 cholangitis	 is	 an	 absolute	 indication	 for	 preoperative	
biliary	drainage	(PBD).	In	the	absence	of	cholangitis,	PBD	of	the	FLR	
is	debated,	because	it	may	cause	cholangitis	that	is	associated	with	
post‐operative	 liver	 failure	 and	 mortality.	 The	 indication	 for	 PBD	
must	therefore	be	cautiously	evaluated	by	a	hepatobiliary	multidis‐
ciplinary	team.
Obstructive	 jaundice	 is	 associated	 with	 a	 pro‐inflammatory	
state.19	Some	series	reported	an	association	between	serum	biliru‐
bin	and	post‐operative	complications,20,21	and	the	authors	therefore	
advocated	 routine	 PBD.	 However,	 a	 randomized	 controlled	 trial	
(RCT)	 for	 patients	 with	 periampullary	 tumours	 found	 an	 increase	
in	perioperative	complications	after	PBD.22	Consequently,	patients	
with	resectable	dCCA	and	a	bilirubin	 level	below	15	mL/dL	should	
undergo	 a	 pancreatoduodenectomy	 without	 preoperative	 biliary	
drainage.	Because	 liver	resection	 in	 jaundiced	patients	was	 judged	
at	higher	 surgical	 risk,	most	 surgeons	 continued	PBD	 in	 jaundiced	
patients	 with	 pCCA.6	 Several	 retrospective	 studies	 reported	 that	
PBD	 is	associated	with	 infectious	complications,	and	cholangitis	 is	
an	independent	prognostic	factor	for	post‐operative	mortality.23,24 









Two	procedures	 to	 drain	 the	 bile	 ducts	 are	 available:	 percuta‐
neous	 transhepatic	 biliary	 drainage	 (PTBD)	 and	 endoscopic	 biliary	
drainage	 (EBD).	 Two	 recent	meta‐analyses,	 found	 a	 higher	 proce‐
dure	conversion,	cholangitis	and	pancreatitis	rate	in	the	EBD	group	






To	 overcome	 the	 morbidity	 of	 EBD,	 endoscopic	 nasobiliary	
drainage	(ENBD)	has	been	proposed	in	Japan.	They	report	a	lower	
rate	 of	 conversion	 to	 PTBD.28	Others	 failed	 to	 show	differences	
when	comparing	ENBD	with	EBD	and	PTBD.29	Among	the	draw‐













2.4 | Portal vein embolization and ALPPS
An	inadequate	FLR	volume	and	function	poses	the	patient	at	risk	
to	post‐hepatectomy	liver	failure	(PHLF).	PVE	aims	to	decrease	the	
risk	of	PHLF	by	occluding	 the	portal	 vein	 to	 the	 side	of	 the	 liver	
that	 is	 resected,	causing	hypertrophy	of	 the	FLR.31,32	 In	 two	sys‐
tematic	 reviews,	preoperative	PVE	was	associated	with	a	relative	
increase	in	FLR	of	about	40%	and	a	2.5%	adverse	events	rate.31,32 
A	more	 recent	 review	details	 the	 four	 largest	 studies	on	PVE	 for	




ists.33	 In	most	 studies,	 cutoffs	 of	 the	 FLR	 range	 from	 20%‐40%,	














Associating	 liver	 partition	 and	 portal	 vein	 ligation	 for	 staged	
hepatectomy	 (ALPPS)	 is	 another	 option	 for	 patients	 with	 a	 small	
FLR.	During	the	first	procedure	of	ALPPS,	 the	 liver	parenchyma	 is	
(partially)	 transected	with	portal	vein	 ligation	of	 the	 liver	with	 the	















into	 the	 right	or	 left	hepatic	ducts	or	 the	biliary	confluence.44	For	








section.46	 Lymphadenectomy	 of	 locoregional	 lymph	 nodes	 in	 the	
hepatoduodenal	ligament	is	recommended,	but	has	a	bigger	impact	
on	staging	than	on	improving	survival.































on	 patients	 with	 locally	 advanced	 pCCA.53	 The	 twelve	 patients	
who	received	preoperative	CRT,	compared	to	the	45	who	did	not,	
showed	 a	 higher	 rate	 of	 R0	 resections	 that	was	 not	 statistically	
different	(83%	vs	64%,	P	=	0.32)	and	no	difference	in	disease‐free	
survival	 (DFS)	 and	 overall	 survival	 (OS).	 The	 phase	 II	 trial	 of	 the	
NACRAC	study	is	currently	in	progress:	twenty‐four	patients	with	
cholangiocarcinoma	 have	 been	 recruited	 and	 R0	 resection	 has	
been	 obtained	 in	 71%.54	 With	 all	 the	 limitations	 of	 the	 studies	
above,	such	as	small	samples	and	different	therapeutic	regimens,	
preoperative	 CRT	 has	 proved	 to	 be	 safe	 and	 seems	 to	 enhance	
R0	 resection	 rate	 for	 (borderline)	 unresectable	 pCCA.	Definitive	
data	 from	the	NACRAC	study	are	awaited	to	determine	whether	


















Outcomes	 for	 patients	 with	 resectable	 pCCA	 depend	 on	 three	
factors:
1.	Tumour	characteristics:	 local	extent	of	 the	tumour,	 tumour	dif‐
ferentiation,	 lymphovascular,	 perineural	 and/or	 microvascular	









recurrent	 disease	mostly	within	 two	 years	 after	 surgery.62,63	 R0‐re‐







Another	 important	 tumour	 characteristic	 is	 tumour	 differen‐
tiation	(well	vs	moderate/poor),	although	not	as	strong	as	R‐status	
and	nodal	involvement.	Other	poor	prognostic	factors	are	lympho‐












resections	 have	 been	 proposed.	 One	 type	 of	 extended	 resection	













The	 rationale	 of	 LT	 in	 patients	 with	 pCCA	 is	 to	 avoid	 two	 unfa‐
vourable	outcomes	of	 surgical	 resection;	 a	positive	margin	and	an	
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inadequate	FLR	with	PHLF.	Furthermore,	LT	 is	effective	 in	 remov‐
ing	 the	 underlying	 liver	 disease,	 such	 as	 PSC.68	 Early	 experience	










administered	 for	 chemosensitization	 during	 radiation	 therapy,	 and	
capecitabine	 administered	 afterward	while	waiting	 LT.73,74	 Staging	
surgery	with	lymph	node	biopsies	is	performed	after	brachytherapy.	

















case	of	 a	 patient	with	 a	 negative	 cytology,	 negative	FISH,	 and	no	
residual	 tumour	 in	 the	 specimen	 after	 transplant	 the	 question	 re‐
mains	whether	the	patient	ever	had	a	cancer.	The	authors	estimate	
this	possibility	to	be	about	15%	of	patients.78	However,	the	high	risk	
of	 recurrence	 after	 transperitoneal	 biopsy	 justifies	 this	 approach	
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new	allocation	policy	was	proposed	allowing	the	use	of	5%	of	donors	




















until	progression.82	They	 reported	prolonged	survival	 in	 those	pa‐
tients	 with	 periductal	 infiltrating	 pCCA	 rather	 than	 in	 those	 with	
mass‐forming	 pCCA.	 The	 overall	 toxicity	 was	 mild.	 In	 this	 study,	
there	was	no	a	control	group,	thus	limiting	the	generalizability	of	the	
conclusions.
Irreversible	electroporation	 (IRE)	 is	 a	promising	 image‐guided	








curative	 surgery.	 IRE	 aims	 to	 avoid	 or	 delay	 local	 progression	 of	
disease	with	progressive	 isolation	of	 sectoral	 and	 segmental	 bile	
ducts.	Martin	 et	 al	 showed	 the	 results	of	 a	 single‐centre	experi‐
ence	on	the	local	control	of	the	biliary	obstructions	in	26	patients	









photo‐sensitizer.	 This	 results	 in	 the	 generation	of	 oxygen	 radicals	
that	 lead	 to	 cancer	 cell	 death.	 Typically,	 5‐aminolevulinic	 acid	 is	
used	as	photo‐sensitizing,	and	the	percutaneous	route	is	preferred	
over	 the	 endoscopic	 route	 because	 of	 lower	 risks,	 increased	 fea‐
sibility,	and	easy	repeatability.86	Some	authors	reported	promising	
results	of	PDT	for	bile	duct	tumours,	with	respect	to	relief	of	jaun‐






can	 be	 achieved	 by	 more	 extensive	 resection,	 particularly	 of	 the	






with	 local	 irradiation	 treatment	 might	 offer	 potential	 –	 once	 ap‐
propriate	targets	for	targeted	therapies	for	this	tumour	have	been	
identified.
Another	option	 to	prevent	 recurrence	after	 resection	could	be	
adjuvant	 treatment.	 So	 far,	 adjuvant	 chemotherapy	 appears	 to	 be	






3  | INTR AHEPATIC 
CHOL ANGIOC ARCINOMA
3.1 | Diagnostic work‐up
Intrahepatic	 cholangiocarcinoma	 (iCCA)	 arises	 in	 the	 biliary	 tree,	
proximal	to	the	second‐order	bile	ducts.	Most	iCCA	patients	are	di‐
agnosed	with	a	large	mass	on	imaging	after	presenting	with	unspe‐





arising	 from	 the	 biliary	 confluence	 or	 main	 hepatic	 ducts.	 iCCA	
can	also	be	diagnosed	in	an	asymptomatic	patient	who	underwent	
imaging	for	elevated	 liver	enzymes	or	a	reason	unrelated	to	 iCCA.	
The	 majority	 of	 iCCA	 patients	 have	 no	 underlying	 liver	 disease.	
Underlying	liver	disease,	however,	is	a	risk	factor	for	iCCA.	Patients	
with	cirrhosis	in	a	screening	programme	for	early	detection	of	HCC	
are	 sometimes	 found	 to	have	 iCCA.	Especially	 small	 iCCA	may	be	
difficult	 to	distinguish	 from	HCC	on	 imaging.	Sometimes,	 the	 final	
diagnosis	is	only	made	at	pathological	examination	after	surgical	re‐
section	or	liver	transplantation.





is	more	 likely	 in	patients	with	HCC.	Serum	IgG4	 is	elevated	 in	pa‐
tients	with	auto‐immune	cholangitis,	which	may	sometimes	present	
as	 an	 intrahepatic	mass.90	However,	not	 all	 patients	with	elevated	





















ment	 and	 progressive	 central	 enhancement.92	Moreover,	MRCP	 is	
superior	in	delineation	of	the	biliary	extent	of	tumours	growing	to‐
wards	the	 liver	hilum	and	causing	biliary	obstruction.	PET‐CT	may	
find	 lesions	 suspicious	 for	metastastic	 disease	 that	were	 not	 visi‐
ble	on	CT.	Unfortunately,	PET‐CT	has	a	low	yield	of	about	10%	for	
finding	occult	metastases	and	a	considerable	risk	of	false‐negative	
















tween	 anticipated	oncological	 benefit	 (ie,	 superior	OS	 and	quality	


















lesion	also	have	a	worse	OS	and	are	 less	 likely	to	benefit	 from	re‐
section.	Several	 studies	 found	a	5‐year	OS	of	 about	10%	with	 re‐
section	 in	 patients	with	multiple	 tumours.95,96	 Resection	 could	 be	





















Staging	 laparoscopy	 should	 be	 considered	 in	 all	 patients	 with	
iCCA	 to	 rule	 out	 occult	 metastastic	 disease.	 This	 risk	 is	 particu‐
larly	 high	 in	 patients	 with	 high	 CA	 19‐9,	 major	 vascular	 invasion	
and	 suspicious	 lymph	 nodes.99	 Exploratory	 laparotomy	 without	
resection	 should	 be	 avoided	 because	 it	 delays	 palliative	 systemic	
chemotherapy.
Suspicious	 lymph	 nodes	 beyond	 the	 hepatoduodenal	 ligament	
should	be	sent	for	frozen	section.	However,	preoperative	assessment	
of	suspicious	aortocaval	and	truncal	 lymph	nodes	with	endoscopic	
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ultrasound	and	 fine	needle	aspiration	 is	preferred.	Guidelines	 rec‐
ommend	to	perform	a	lymphadenectomy	in	all	patients	with	resect‐
able	iCCA.99	For	optimal	staging,	the	8th	edition	of	the	AJCC	staging	















P	=	0.097).101	 The	 BCAT	 trial	 found	 no	 survival	 difference	 be‐
tween	 gemcitabine	with	 observation	 (HR	 1.01;	 95%	CI	 0.70‐1.45;	









Preoperative	 systemic	 chemotherapy	 for	 patients	with	 resect‐
able	or	unresectable	iCCA	has	not	been	evaluated	in	an	RCT.	A	multi‐
national	study	included	62	patients	with	resectable	or	unresectable	
iCCA	who	 received	 preoperative	 systemic	 chemotherapy.104	 They	
found	 a	 median	 OS	 of	 47	months	 for	 patients	 who	 underwent	 a	
complete	 resection	 after	 preoperative	 chemotherapy.	 In	 a	 recent	
study	of	74	patients	with	unresectable	iCCA,	39	patients	(53%)	un‐
derwent	a	resection	after	a	median	of	six	cycles	of	systemic	chemo‐
therapy.	 The	median	OS	was	 24	months	 after	 completion	 of	 both	











have	 a	 mortality	 rate	 of	 about	 1%	 in	 high‐volume	 centres.	 Most	
patients	with	 iCCA	 (75%)	will	 require	 an	 (extended)	 hemihepatec‐









































Surgical	 resection	 is	 the	preferred	 treatment	 for	 resectable	 iCCA.	
However,	a	lesion	of	less	than	2	or	3	cm	located	centrally	in	the	liver	
could	be	considered	for	 thermal	ablation	 (eg,	RFA	or	MWA)	 in	pa‐
tients	with	a	high	surgical	risk	(eg,	cirrhosis).	The	main	drawback	of	
thermal	ablation	 is	an	 increased	 risk	of	 local	 recurrence.	Omission	
of	lymphadenectomy	is	less	concerning:	nodal	metastasis	is	unlikely	
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in	 small	 lesions,	 and	 removing	positive	 lymph	nodes	has	not	been	
shown	to	improve	survival.
Locoregional	 treatments	 are	 mainly	 applied	 in	 patients	 with	
unresectable	 disease.	 The	median	OS	with	 systemic	 chemother‐
apy	 (gemcitabine	 with	 cisplatin)	 for	 patients	 with	 unresectable	
iCCA	 is	 <1	year	 with	 very	 few	 survivors	 beyond	 2	years.100,114 
Most	patients	with	iCCA	eventually	die	from	tumour	burden	lim‐
ited	to	the	liver.	Progressive	disease	in	the	liver	eventually	causes	
biliary	obstruction	and	 liver	 failure.	Locoregional	 treatments	aim	
to	 improve	 survival	 by	 controlling	disease	 in	 the	 liver	 as	 long	 as	
possible.	If	local	control	is	succesful,	most	patients	will	eventually	
die	from	distant	metastases.






metastases.	 Hepatic	 arterial	 infusion	 pump	 (HAIP)	 chemotherapy	
with	floxuridine	has	been	investigated	in	a	study	of	104	patients.117 
















for	 biliary	 cancer	 found	 conflicting	 results.	 Better	 adjuvant	 treat‐




preoperative	 and	 adjuvant	 setting	based	on	molecular	 profiling	of	
tumours	may	further	improve	outcomes.
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